Research & Development

Apotex and Grünenthal sign deal for Nebido Canadian distribution

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism.

PrimeGen US and DT Cloud Star sign $1.5bn merger agreement

PrimeGen US and DT Cloud Star Acquisition have entered a definitive business combination agreement at an implied equity value of around $1.5bn.

Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer

Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with fulvestrant, for human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treatment.

CEPI and Samsung Biologics partner to boost global vaccine preparedness

The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance the preparedness of global vaccine production for pandemic threats and future epidemics.

SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal

SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic acid interferences (RNAi) programmes utilising SanegeneBio’s technology platform.

CIRM unveils RAPID funding programme for rare diseases

The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and Delivery (RAPID) funding programme, setting aside $100m over two years.

IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation

IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas. 

Repertoire and Lilly join hands on autoimmune disease therapies

Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases.

Sensorion announces $71.9m reserved offering to expand gene therapy pipeline

Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.